The Amplatzer patent foramen ovale (PFO) occluder snagged mostly positive votes from an FDA advisory committee on Tuesday. Members apparently considered the weak evidence for the device’s effectiveness — as demonstrated by three separate trials — less important than the perceived clinical need.
Bleeding was common in patients receiving triple oral antithrombotic therapy over a median of 4 months, a single-center study suggested, occurring at a rate of 26.7%. In particular, events were more likely in patients with drug-eluting stents than their peers on bare-metal stents (adjusted odds ratio 1.52, 95% CI 1.14-2.04).
The FDA reclassified external cardiac compressors from class III to class II. CPR aids with guides to assist rescuers also moved to class II, while those without guides went to class I.
A 12-week regimen of cardiac rehabilitation was linked to better exercise tolerance after balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. “This promising new treatment strategy does not require a prolonged hospital stay for initial in-hospital training and did not lower patient compliance,” according to the researchers in Japan.
Society of NeuroInterventional Surgery has launched “Get Ahead of Stroke,” a campaign to educate emergency services and to advocate for mechanisms that deliver stroke patients to intervention-ready centers faster.
A former employee stands accused of stealing intellectual property from Covidien and Edwards Lifesciences in order to start his own cardiac device company in China.
The contraindication for cardiac resynchronization therapy expands to patients with a QRS below 130 msec, according to new guidelines from the European Society of Cardiology.
For patients with atrial fibrillation and only one CHA2DS2VASc risk factor — unrelated to gender — is oral anticoagulation appropriate? Perhaps, a study suggested, tying anticoagulation to fewer strokes and systemic embolisms in this group.